PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, has increased its share capital by 8,311 shares as a consequence of the exercise of employee warrants. The increase was effected without any preemption rights for the existing shareholders of the company or others. The shares were subscribed in cash at the price of €2.32, each share having a nominal value of €0.25. As a result, the total number of shares has increased from 31,482,333 to 31,490,644 and Onxeo’s share capital amounts to €7,872,661. About Onxeo Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives. Key products at advanced development stage are: Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis Beleodaq® (belinostat): Registered and available in the USA for peripheral T -cell lymphoma For more information, visit the website www.onxeo.com Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward -looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (http://www.amf-france.org) or on the company’s website (www.onxeo.com). Onxeo Judith Greciet, +33 1 45 58 76 00 CEO j.greciet@onxeo.com or Nicolas Fellmann, +33 1 45 58 76 00 CFO n.fellmann@onxeo.com or Caroline Carmagnol / Sophie Colin – Alize RP +33 6 64 18 99 59 / +33 6 31 13 76 20 caroline@alizerp.com / scolin@alizerp.com
Capital Increase in Onxeo as a Result of Employee Warrant
Top 10 Most Recent News Articles
AppLovin Legal Woes: A Deep Dive into Investor Claims
AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...
Continue Reading
Novo's Research Unlocks New Insights into Food Noise
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest
Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...
Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era
The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...
Continue Reading
Uber Data Breach: Class Action Investigation Begins
When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...
Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes
Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....
Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale
Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...
Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue ReadingTop 5 Most Recently Viewed Articles
ARK Venture Fund Invests in Umoja's Innovative Cancer Research
ARK Venture Fund Invests in Umoja's Innovative Cancer Research Cathie Wood's ARK Venture Fund has made a notable investment in Umoja's Series C funding round, marking a significant milestone for the biotech company. Umoja is dedicated to pioneering a transformative approach to cancer treatment, focusing on enhancing the patient's immune response through novel techniques....
Continue Reading
Hooker Furnishings Shows Solid Sequential Growth in Q2 Results
Hooker Furnishings' Second Quarter Performance Hooker Furnishings Corporation (NASDAQ: HOFT), a well-established name in the home furnishings industry for more than a century, recently revealed its financial results for the second quarter of fiscal 2025. The company demonstrated resilience in the face of challenging market conditions. Sales Performance Insights Typically...
Continue Reading
Pulmonx Achieves Remarkable Financial Growth in 2024
Pulmonx Achieves Record Financial Success in 2024 Pulmonx Corporation (Nasdaq: LUNG) has made significant strides in its financial performance, demonstrating a remarkable growth trajectory throughout 2024. This globally recognized leader in minimally invasive lung disease treatments reported promising results that highlight its strong business model and commitment to...
Continue Reading
Blue Hat Secures $4.3 Million Through Direct Share Offering
Blue Hat Interactive Entertainment Technology Engages in Direct Share Offering Recently, Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) made headlines by announcing its entry into securities purchase agreements allowing it to raise an impressive $4.3 million. This initiative is aimed at bolstering the company's financial stability and enhancing its market...
Continue Reading
Celebrating Innovation: PTx Trimble's OutRun Secures Award
PTx Trimble Triumphs with OutRun at the Davidson Prize OutRun Autonomous Grain Cart Now Available in the U.S. PTx Trimble, a collaboration between AGCO and Trimble that started in 2024, has made headlines by launching OutRun, a revolutionary autonomous grain cart that has just clinched the prestigious Davidson Prize at Commodity Classic 2025. This accolade recognizes...
Continue Reading